Myths vs facts: CYP1A2 and Wechseljahre

CYP1A2 encodes an enzyme that metabolizes caffeine and certain hormones like estrogen. During menopause, estrogen levels drop, which could theoretically alter CYP1A2 activity, but the evidence is limited and inconsistent. A common myth is that testing CYP1A2 variants (e.g., rs4253778) can guide personalized nutrition or hormone therapy for menopause. In reality, effect sizes are small, and no robust clinical trials show that such genetic information improves weight management or hot flash relief during menopause. Most evidence comes from GWAS or mechanistic studies, not from interventional trials. While some women may feel better reducing caffeine during menopause, this is based on individual tolerance, not genetics. Be cautious of products claiming DNA-based menopause diets; they overstate genetic influence. A balanced diet, exercise, and medical supervision remain the evidence-based approach.